1- World Health Organization. Assessment of fracture risk and its application to screening for post-menopausal osteoporosis. WHO technical report series. Geneva : WHO, 1994
2- Meunier PJ. Progrès dans le diagnostic et la prise en charge. Martin Dunitz, Londres, 1999
3- Comment prévenir les fractures dues à l’ostéoporose ? HAS fiche de synthèse mai 2007. www.has-sante.fr
4- Gangji V, Appelboom T. Analgesic effect of intravenous pamidronate in chronic back pain due to osteoporotic vertebral fractures. Clin Rheumatol 1999:18 ; 266-7
5- Legroux-Gérot I, Chastanet P, Cotten A et al. Indications de la vertébroplastie : fractures vertébrales ostéoporotiques. Réfléxions Rhumatologiques. 2003 ; 60(7) :13-6
6- Cyteval C. Essais randomisés de la vertébroplastie pour le traitement de la douleur des fractures vertébrales par insuffisance. J Radiol2009 ; 90 : 1785-6
7- Cyteval C. Suivi prospectif du risque fracturaire après vertébroplastie utilisant un faible volume de ciment chez des patients ostéoporotiques. J Radiol 2008 ; 89 : 797-801
8- Malliopoulos X. Tassement vertébral ostéoporotique algique : prise en charge rééducative. Réfléxions Rhumatologiques 2000 ; 27(4) :20-3
9- Liberman UA, Weiss SR, Bröll J et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med1995 ; 333 : 1437-43
10- Black DM, Cummings SR, Karpf DB et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996 ; 348 : 1535-41
11- Harris ST, Watts NB, Genant HK et al. Effects of risedronate treatment on vertebral and non vertebral fractures in women with postmenopausal osteoporosis : A randomized controlled trial. JAMA 1999 ; 282 : 1344-52
12- Reginster J, Minne HW, Sorenson OH et al ; Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int2000 ; 11 : 83-91
13- Boonen S, McClung MR, Eastell R et al. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older : implications for the use of antiresorptive agents in the old and oldest old.J Am Geriatr Soc 2004 ; 52 : 1832-39
14- Chesnut CH III, Skag A, Christiansen C et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004 ; 19 : 1241-9
15- Black DM, Delmas PD, Eastell R et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis ; N Engl J med 2007 ; 356 : 1809-22
16- Woo SB, Hellstein JW, Kalmar JR. Bisphosphonates and osteonecrosis of the jaws. Ann Int Med 2006 ; 144 : 753-61
17- Ettinger B, Black DM, Mitlak BH et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifène : results from a 3-year randomized clinical trial.JAMA 1999 ; 282 : 637-45
18- Cummings SR, San Martin J, Mc Clung MR et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med2009 ; 361 : 756-65
19- Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001 ; 344 : 1434-41
20- Meunier PJ, Roux C, Seeman E et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004 ;350:459-6
Mise au point
Troubles psychiatriques : quand évoquer une maladie neurodégénérative ?
Étude et pratique
Complications de FA, l’insuffisance cardiaque plus fréquente que l’AVC
Cas clinique
L’ictus amnésique idiopathique
Recommandations
Antibiothérapies dans les infections pédiatriques courantes (2/2)